You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 15 skipping alterations.
Yourgene will use its manufacturing facility at Citylabs in Manchester to ramp up production of the test, which was developed by Novacyt's Primerdesign division.
The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.
OpGen also reported full-year growth was driven by revenue increases for its Acuitas AMR Gene Panel and Acuitas Lighthouse informatics platform.
The assay, which is also CE-IVD-marked, detects SARS-CoV-2 ORF1a and N genes and has a limit of detection of 20 copies per mL using a 400 µL sample.
The firm licensed the assay for detecting SARS-CoV-2 from Hackensack Meridian Health and will adapt it for the T2Dx instrument.
As part of the joint venture, Todos will be responsible for securing US regulatory approval for a coronavirus rapid point-of-care kit.
The deal took effect immediately and shipments have to Spain, France, Germany, and the UK have begun.
SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.
The 45-minute test was developed by BioMérieux subsidiary BioFire Defense and can be used on the company's FilmArray and FilmArray Torch systems.
The international initiative will aim to produce information, tools, and policy models to help assess and prevent genetic discrimination.
The group will use IsoPlexis' single-cell proteomics platform to analyze immune cells from patients who have been diagnosed or recovered from COVID-19.
The 30-minute PCR assay, read visually, uses the company's Accula system, which is designed for use at the point of care.
The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.
The sequencing-based test is designed to detect mutations that cause resistance to 15 first- and second-line antibiotics used to treat tuberculosis.
The company plans to use the net proceeds to pay in part for its anticipated acquisition of Qiagen, as well as for general corporate purposes.
The firm now expects to complete the development work needed to request Emergency Use Authorization for the new panel.
The company's in vitro diagnostic qRT-PCR test detects viral RNA and targets three genes of the SARS-CoV-2 virus: the N, Orf1ab, and E genes.
Researchers found that small-molecule inhibitors targeting oncogenic signal transduction or epigenetic regulation can alter specific 3D interactions in leukemia.
The molecular assay is expected to require a pharyngeal throat swab to deliver diagnostic results on a paper strip in under 30 minutes.
An analysis of lung adenocarcinoma brain metastases uncovered more frequent amplifications or deletions in a handful of genomic regions, pointing to potential drivers.
An analysis of biobank data from Japan, the UK, and Finland found the link between obesity and lifespan was stronger among individuals with European ancestry.
The company said the test achieved 100 sensitivity and 100 percent specificity in a study of 210 samples that included 44 from COVID-19 patients.
The consortium, which spans more than a dozen UK cities, will sequence patient samples to understand the spread and evolution of the novel coronavirus.
Last week, GenomeWeb's readers were most interested in a genomic analysis that concluded that the SARS-CoV-2 virus evolved from naturally occurring strains.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.